Product Description
Menarini is developing Dexketoprofen as a treatment for Moderate to Severe Acute Pain in Patients With Acute Low Back Pain. (Sourced from: https://clinicaltrials.gov/study/NCT05170841)
Mechanisms of Action: COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Bulgaria | Chile | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Menarini
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Mexico
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Acute Pain|Low Back Pain|Pain, Postoperative|Renal Colic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| WHIPLASH | P3 |
Completed |
Acute Pain|Low Back Pain |
2023-04-24 |
|
| CTR20232798 | P3 |
Not yet recruiting |
Renal Colic|Acute Pain|Low Back Pain|Pain, Postoperative |
None |